300006 Stock Overview
Engages in the research and development, manufacture, and sale of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Chongqing Lummy Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.58 |
| 52 Week High | CN¥5.46 |
| 52 Week Low | CN¥2.03 |
| Beta | 0.60 |
| 11 Month Change | 14.50% |
| 3 Month Change | 89.26% |
| 1 Year Change | 5.53% |
| 33 Year Change | -23.67% |
| 5 Year Change | -6.34% |
| Change since IPO | -48.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300006 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.6% | -1.5% | -2.1% |
| 1Y | 5.5% | -9.4% | 2.8% |
Return vs Industry: 300006 exceeded the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 300006 matched the CN Market which returned 5.4% over the past year.
Price Volatility
| 300006 volatility | |
|---|---|
| 300006 Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300006's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300006's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 800 | Rongzhao Qiu | www.cqlummy.com |
Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company provides antibacterial, antifungal, antiviral agent, acid-base balance nutritional, liver auxiliary, Chinese patent, base large infusion drugs; American ginseng; and drugs for the treatment of tumors, as well as digestive, immune, blood, nervous, cardiovascular, and endocrinology systems. It also offers sodium bicarbonate injection.
Chongqing Lummy Pharmaceutical Co., Ltd. Fundamentals Summary
| 300006 fundamental statistics | |
|---|---|
| Market cap | CN¥4.84b |
| Earnings (TTM) | CN¥19.17m |
| Revenue (TTM) | CN¥856.48m |
252.3x
P/E Ratio5.6x
P/S RatioIs 300006 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300006 income statement (TTM) | |
|---|---|
| Revenue | CN¥856.48m |
| Cost of Revenue | CN¥306.70m |
| Gross Profit | CN¥549.78m |
| Other Expenses | CN¥530.61m |
| Earnings | CN¥19.17m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.018 |
| Gross Margin | 64.19% |
| Net Profit Margin | 2.24% |
| Debt/Equity Ratio | 18.7% |
How did 300006 perform over the long term?
See historical performance and comparison